May 18, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CLEVELAND — Researchers are beginning to understand the pathogenesis of dermatomyositis, leading to new, targeted therapies for the disease, according to a speaker at Cleveland Clinic’s Medical Dermatology Therapy Update IV. “Dermatomyositis is starting to have its moment,” Lisa Christopher-Stine, MD, MPH, director of Johns Hopkins Myositis Precision Medicine Center of Excellence, told
May 18, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…

DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according…

Treatment with once-daily brepocitinib improved skin disease, muscle and physical function measures for adults with…

The emergence of biologic therapies ushered in an era of unprecedented positive outcomes for patients with rheumatic and…

People with dermatomyositis displayed a greater prevalence of concurrent postural orthostatic tachycardia syndrome compared with…

VIDEO: Immunotherapies offer new opportunities in relapsed, refractory myeloma